Qirong Yang

Zicheng Liu, Siyuan Li, Zhiyuan Chen et al.

The interactions between DNA, RNA, and proteins are fundamental to biological processes, as illustrated by the central dogma of molecular biology. Although modern biological pre-trained models have achieved great success in analyzing these macromolecules individually, their interconnected nature remains underexplored. This paper follows the guidance of the central dogma to redesign both the data and model pipeline and offers a comprehensive framework, Life-Code, that spans different biological functions. As for data flow, we propose a unified pipeline to integrate multi-omics data by reverse-transcribing RNA and reverse-translating amino acids into nucleotide-based sequences. As for the model, we design a codon tokenizer and a hybrid long-sequence architecture to encode the interactions between coding and non-coding regions through masked modeling pre-training. To model the translation and folding process with coding sequences, Life-Code learns protein structures of the corresponding amino acids by knowledge distillation from off-the-shelf protein language models. Such designs enable Life-Code to capture complex interactions within genetic sequences, providing a more comprehensive understanding of multi-omics with the central dogma. Extensive experiments show that Life-Code achieves state-of-the-art results on various tasks across three omics, highlighting its potential for advancing multi-omics analysis and interpretation.

Siyuan Li, Kai Yu, Anna Wang et al.

Modeling genomic sequences faces two unsolved challenges: the information density varies widely across different regions, while there is no clearly defined minimum vocabulary unit. Relying on either four primitive bases or independently designed DNA tokenizers, existing approaches with naive masked language modeling pre-training often fail to adapt to the varying complexities of genomic sequences. Leveraging Token Merging techniques, this paper introduces a hierarchical architecture that jointly optimizes a dynamic genomic tokenizer and latent Transformers with context-aware pre-training tasks. As for network structures, the tokenization module automatically chunks adjacent bases into words by stacking multiple layers of the differentiable token merging blocks with local-window constraints, then a Latent Encoder captures the global context of these merged words by full-attention blocks. Symmetrically employing a Latent Decoder and a Local Decoder, MergeDNA learns with two pre-training tasks: Merged Token Reconstruction simultaneously trains the dynamic tokenization module and adaptively filters important tokens, while Adaptive Masked Token Modeling learns to predict these filtered tokens to capture informative contents. Extensive experiments show that MergeDNA achieves superior performance on three popular DNA benchmarks and several multi-omics tasks with fine-tuning or zero-shot evaluation, outperforming typical tokenization methods and large-scale DNA foundation models.

Zekai Lin, Haoran Sun, Yucheng Guo et al.

Distinguishing pathogenic mutations from benign polymorphisms remains a critical challenge in precision medicine. EnTao-GPM, developed by Fudan University and BioMap, addresses this through three innovations: (1) Cross-species targeted pre-training on disease-relevant mammalian genomes (human, pig, mouse), leveraging evolutionary conservation to enhance interpretation of pathogenic motifs, particularly in non-coding regions; (2) Germline mutation specialization via fine-tuning on ClinVar and HGMD, improving accuracy for both SNVs and non-SNVs; (3) Interpretable clinical framework integrating DNA sequence embeddings with LLM-based statistical explanations to provide actionable insights. Validated against ClinVar, EnTao-GPM demonstrates superior accuracy in mutation classification. It revolutionizes genetic testing by enabling faster, more accurate, and accessible interpretation for clinical diagnostics (e.g., variant assessment, risk identification, personalized treatment) and research, advancing personalized medicine.